Clinical trials: Influenza Immunization
Influenza Virus Infection, Trained Immunity
Effects of BCG on Influenza Induced Immune Response
In the present study, the investigators want to investigate whether prior BCG-vaccination improves the efficacy of influenza ("the flu") vaccination in young and/or old healthy volunteers and consequently could protect against…
- Trial name
- NCT02114255
- Testing
- BCG
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Influenza
Swine Flu (Influenza A H1N1) Follow on Vaccine Study
In 2009 the World Health Organization (WHO) declared the Influenza A H1N1 (swine 'flu) outbreak the first global pandemic of this century.
- Trial name
- NCT01239537
- Testing
- Seasonal Flu vaccine
- Where
- 5 sites in United Kingdom
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pregnancy Related, Influenza Virus Vaccine Adverse Reaction
Maternal and Fetal Outcomes Following Influenza Vaccination in Pregnancy
This is a nationwide cohort study to assess maternal and fetal outcomes following vaccination with a quadrivalent influenza vaccine (QIV) during pregnancy.
- Trial name
- NCT04579822
- Testing
- influenza vaccine
- Volunteers
- 300,000 people, healthy volunteers welcome
- Sponsor
- Sungkyunkwan University
Influenza
Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)
The aim of the present dose ranging study is to evaluate the safety, tolerability and immunogenicity of two doses of twelve different formulations of a Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine, adjuvanted with…
- Trial name
- NCT00812019
- Testing
- Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59
- Where
- 2 sites in United States, Germany
- Volunteers
- 753 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Influenza Immunisation
Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination
This was a Phase IV open label and single arm study, with the aim of enrolling up to 55 healthy males and non-pregnant females in a single site, age 18-49 years old, inclusive.
- Trial name
- NCT02485639
- Testing
- Influenza Virus Vaccine Inactivated
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Control of Epidemic Influenza Through a School-based Influenza Vaccination Program
The main purpose of this study is to learn if influenza vaccines (live attenuated and inactivated influenza vaccines), when given to school-aged children 4 to 18 years of age, can stop or lessen the influenza (flu) outbreak in…
- Trial name
- CEI (NCT00138294)
- Testing
- live attenuated and inactivated influenza vaccines
- Where
- 2 sites in United States
- Volunteers
- 29,255 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Healthy
Training Study to Characterize Biomarkers to Flu Vaccines
It is thought that vaccines trigger innate inflammatory responses to induce antigen-specific adaptive immunity (the desired effect), but excessive inflammation may lead to serious inflammatory complications or unwanted side…
- Trial name
- NCT01771367
- Testing
- Fluad, Agrippal
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Influenza Vaccine, Cost-Benefit Analysis
Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome
Flu vaccination, as well as being effective to prevent seasonal influenza, decreases staff illness and absenteeism and reduces costs resulting from loss of productivity.
- Trial name
- NCT06304038
- Testing
- Flu Vaccine
- Where
- Italy
- Volunteers
- 5,483 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Influenza
Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)
The present study aims to evaluate safety, tolerability and immunogenicity of three lots of Chiron's cell-derived subunit influenza vaccine in healthy adult subjects as compared to a conventional egg-derived control vaccine…
- Trial name
- NCT00310804
- Testing
- Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV), Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV), Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)
- Where
- 2 sites in Lithuania
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Influenza, Human
Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children
The goal of this clinical trial is to assess tolerability, reactogenicity, safety and immunogenicity of the Flu-M Tetra vaccine as compared to the VaxigripTetra vaccine in terms of prevention of influenza in children aged 6…
- Conditions
- Influenza, Influenza, Human, Influenza Viral Infections, Vaccine Reaction
- Trial name
- NCT05739474
- Testing
- Influenza vaccine [inactivated]
- Where
- 7 sites in Russia
- Volunteers
- 948 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Vaccination; Infection
Mood and Influenza Vaccine Response: A Feasibility Trial
This study is a 2-arm, parallel, randomised controlled feasibility trial of a brief video intervention designed to induce positive affect (mood) in older adults in primary care settings prior to the receipt of influenza…
- Trial name
- NCT03144518
- Testing
- Positive Affect Intervention, Neutral Control Intervention, Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
- Where
- United Kingdom
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Influenza A Virus, H1N1 Subtype
Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.
This project may help to answer several fundamental questions related to public health regarding vaccination against influenza viruses and regarding the influenza A(H1N1)v pandemy: What is the immunologic efficacy in terms of…
- Trial name
- FLU-HOP (NCT01063608)
- Testing
- Anti-H1N1v Vaccine
- Where
- 2 sites in France
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Influenza
Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults
This is a Phase I/II, randomised, multicentre, partially double-blind (group 1, 2, 4 and 5), parallel-group study designed to primarily evaluate the safety, tolerability and immune response in older adults (age 50 to 75 years)…
- Trial name
- NCT03437304
- Testing
- Immunose™ FLU 1%, Immunose™ FLU 2%, 200 μl, Immunose™ FLU 2%, 300 μl
- Where
- 5 sites in Sweden
- Volunteers
- 298 people, healthy volunteers welcome
- Sponsor
- Eurocine Vaccines AB
Heterologous Effects of Vaccines
Heterologous Effect of Diptheria, Tetanus, Acellular Pertussis Vaccination on Influenza Challenge in the Elderly
Vaccines can have non-targeted or heterologous (also called non-specific) immunological effects on the immune system i.e. effects other than inducing an immune response against the disease targeted by the vaccine.
- Trial name
- NCT02765126
- Testing
- Seasonal influenza vaccine, Diphtheria-tetanus-acellular pertussis vaccine
- Where
- Australia
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Clifford Craig Medical Research Trust
Influenza
Comparison of Delivery Routes of Flu Vaccine in Adults
This protocol is to compare the immune response of different influenza vaccines given by two different routes of administration in healthy adults ages 18 to 64 years.
- Trial name
- NCT00170547
- Testing
- Trivalent inactivated influenza vaccine
- Where
- 10 sites in United States
- Volunteers
- 1,597 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never received influenza vaccination.
- Trial name
- NCT01059617
- Testing
- GSK Biologicals' FluLaval®, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
- Where
- 3 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline